Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Clinical trial NCT04449861 · COMPLETED

Trial details

NCT number: NCT04449861
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Small Cell Lung Carcinoma Extensive Disease

Start date: 2020-12-07
Primary completion: 2023-03-30
Enrollment: 166

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.